On October 29th, 2024, Vaxinano, a trailblazing biotech company focused on creating nasal vaccines for both prevention and treatment, successfully secured €6 million in a recent funding round. This significant capital injection will enable Vaxinano to accelerate the advancement of its primary vaccines targeting critical diseases like leishmaniasis, toxoplasmosis, and colibacillosis, bringing them closer to clinical trials. The funding round was led by prominent investors, including TCD Capital, Captech Santé, Nord France Amorçage (NFA), Wiseed, a group of angel investors, and BPI France.
With this investment, Vaxinano is poised to leverage its innovative STELLAR-NP technology, a groundbreaking nanoparticle-based platform designed to optimize vaccine delivery and efficacy. Using biodegradable nanoparticles, STELLAR-NP targets both human and veterinary health, providing a scalable solution to address critical infectious diseases and emerging viral threats. This unique approach enables non-invasive nasal delivery, reducing discomfort and enhancing patient compliance while simplifying global distribution.
Jonathan Stauber, CEO of Vaxinano, highlighted the impact of this funding milestone: “This investment marks a major step in our mission to commercialize our vaccine platform and prepare our candidates for the clinical phase. We are grateful to have the support of a respected group of investors as we expand our team and advance our vaccine pipeline to meet pressing healthcare needs.”
Didier Betbeder, Vaxinano’s Founder and CSO, shared his perspective: “Stellar-NP technology has the potential to reshape the vaccine landscape by delivering more effective and cost-efficient solutions, a crucial advancement as we face the risk of emerging pandemics.”
With this infusion of funding, Vaxinano is well-positioned to lead in the development of innovative, accessible vaccine solutions, marking a significant milestone for the future of vaccine technology.